Gonorrhea Therapeutics Global Market Report 2025

The gonorrhea therapeutics market size has grown strongly in recent years. It will grow from $1.88 billion in 2024 to $1.98 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth during the historic period can be credited to the rising resistance of Neisseria gonorrhoeae, the increasing prevalence of gonorrhea, the growing impact of antimicrobial resistance (AMR), heightened antibiotic resistance, and the expanding use of dual therapy treatments.

The gonorrhea therapeutics market size is expected to see strong growth in the next few years. It will grow to $2.42 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be credited to the rising incidence of sexually transmitted infections, a growing focus on personalized medicine, increasing antibiotic resistance patterns, a higher prevalence of gonorrhea, and the growing demand for effective treatment. Key trends include technological advancements, the development of advanced diagnostic tests, new therapeutics, combination therapies, and regulatory support for expedited drug approvals.

The rising incidence of sexually transmitted infections (STIs) is expected to drive the growth of the gonorrhea therapeutics market in the coming years. STIs are infections transmitted through sexual contact and are caused by bacteria, viruses, or parasites. The increase in STIs is attributed to factors such as unprotected sex, lack of awareness or education, a higher number of sexual partners, reduced condom use, and inadequate or delayed testing and treatment. Gonorrhea therapeutics play a crucial role in treating STIs by targeting the Neisseria gonorrhoeae bacteria, preventing complications, and reducing transmission. For example, in June 2024, the National Institute for Public Health and the Environment, a Netherlands-based government agency, reported a significant rise in gonorrhea cases diagnosed at SHCs, increasing from 10,600 in 2022 to 13,853 in 2023, reflecting a 31% year-over-year growth. This growing prevalence of STIs is fueling the expansion of the gonorrhea therapeutics market.

Leading companies in the gonorrhea therapeutics market are focused on developing innovative solutions, such as rapid polymerase chain reaction (PCR) tests, to enable quick and accurate pathogen detection and antibiotic resistance analysis at the point of care. A rapid PCR test is a diagnostic tool that amplifies and detects specific DNA or RNA sequences, allowing for fast identification of pathogens or genetic material. For instance, in February 2024, Visby Medical, Inc., a US-based medical technology company, introduced a gonorrhea test that includes an antimicrobial resistance check. This rapid diagnostic test identifies the presence of Neisseria gonorrhoeae, the bacteria responsible for gonorrhea, while also assessing its susceptibility to ciprofloxacin, an antibiotic to which some gonorrhea strains have developed resistance. The test is part of a portable, instrument-free PCR platform that allows immediate testing at the point of care. Developed with funding from the US non-profit organization CARB-X, the company plans to expand the test to detect other sexually transmitted infections, including Chlamydia trachomatis and Trichomonas vaginalis, in men.

In November 2024, the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a US-based biopharmaceutical company, partnered with the Clinton Health Access Initiative (CHAI) to enhance antimicrobial resistance (AMR) response and address gonorrhea treatment challenges. This collaboration aims to assess clinical needs and overcome market barriers for gonorrhea diagnostics, prevention, and treatment in low- and middle-income countries, with a focus on drug-resistant Neisseria gonorrhoeae to improve patient care and expand access to effective AMR solutions. CHAI, a US-based health organization, works to improve access to gonorrhea therapeutics, including diagnostics, treatments, and preventive strategies.

Major players in the gonorrhea therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, GlaxoSmithKline plc, Becton Dickinson and Company, Hologic Inc., Aurobindo Pharma Limited, Innoviva Inc., Debiopharm Group, Achilles Vaccines S.r.l., Melinta Therapeutics LLC, VenatoRx Pharmaceuticals Inc., Evofem Biosciences Inc., Recce Pharmaceuticals Ltd., Therapyx Inc., Entasis Therapeutics Inc., Apotex Inc., Alopexx Pharmaceuticals LLC, and Summit Therapeutics Inc.

North America was the largest region in the gonorrhea therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gonorrhea therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gonorrhea therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Gonorrhea therapeutics refer to treatments and medications used to manage and cure gonorrhea, a sexually transmitted infection (STI) caused by *Neisseria gonorrhoeae. These treatments primarily rely on antibiotics, often administered in combination to prevent resistance and ensure effective bacterial eradication.

The main classes of gonorrhea therapeutics include antibiotics, combination therapy, and monotherapy. Antibiotics are specifically designed to eliminate the bacteria responsible for gonorrhea, commonly including drugs such as azithromycin and ceftriaxone. These treatments are administered through oral, intravenous, and intramuscular routes and are tailored for different age groups, including pediatric, adult, and geriatric patients. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, while the primary end users comprise hospitals, clinics, and home care settings.

The gonorrhea therapeutics market research report is one of a series of new reports that provides gonorrhea therapeutics market statistics, including the gonorrhea therapeutics industry global market size, regional shares, competitors with the gonorrhea therapeutics market share, detailed gonorrhea therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the gonorrhea therapeutics industry. This gonorrhea therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gonorrhea therapeutics market consists of revenues earned by entities by providing services such as diagnostic testing services, sexual health and counseling services, telemedicine, and online consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The gonorrhea therapeutics market also includes sales of pediatric formulations, single-dose regimens, sulfonamides, and penicillin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.